Follow

Asarina Pharma AB

Nasdaq First North GM Stockholm (Sweden)

Asarina Pharma is a Swedish biotech company focusing on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
News
1 2 3 4 5
Show

20

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
ASAP
SE0011641794
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Asarina Pharma AB with ticker ASAP
Status
Active
Amount of instruments
18 744 524
Currency
SEK
First trading date
24 Sep 2018
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Set-off issue
Sign in to buy
Directed issue
Sign in to buy
People
Peter Norkild
CEO
Paul de Potocki
Chairman of the board
Erin Gainer
Board member
Marianne Kock
Board member
Mathieu Simon
Board member
Company Details
Sector
HEALTH CARE

Address
Fogdevreten 2
Zip code
171 65
City/district
Solna
Country
Sweden (SE)
Registration number
556698-0750
LEI code
549300PP1GKOHKYQ6K97
First trade date
24 Sep 2018
Registration date
06 Feb 2006
Short name
Asarina

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More